NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Stock Analysis and Metrics

Neuroone Medical Technologies

NASDAQ: NMTC

$1.96 ▲ +0.11 (+5.95%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap7.99 Mn

P/E-2.26

P/S0.87

Div. Yield0.00

Revenue Growth (1y) (Qtr)34.29

Add ratio to table…

About

NeuroOne Medical Technologies Corporation is a medical technology company that develops thin film electrode technology for diagnostic, ablation and deep brain stimulation applications in brain-related conditions such as epilepsy and Parkinson’s disease, for pain management throughout the body, and for drug delivery combined with recording and stimulation capabilities. Its portfolio includes FDA-cleared products such as the Evo Cortical and Evo sEEG electrodes for intracranial monitoring, the OneRF Brain Ablation System for lesion creation, and the OneRF TN Ablation System for trigeminal neuralgia treatment.

The company generates revenue primarily from the sale of its cleared neurotechnology products to hospitals and surgical centers. Under an exclusive distribution agreement with Zimmer Biomet Holdings Inc., Zimmer promotes and sells the Evo Cortical, Evo sEEG and OneRF Brain Ablation System, contributing approximately $9.1 million of product revenue in fiscal 2025. Revenue also stems from the limited market release of the OneRF TN Ablation System initiated in December 2025 and from upfront and milestone payments associated with the Zimmer partnership.

NeuroOne Medical Technologies Corporation competes with established medical device firms and emerging entrants across its target markets. In epilepsy diagnostics, its Evo Cortical and Evo sEEG products face competition from Ad-Tech Medical Instrument Corporation, PMT Corporation and Dixi Medical. For neuro‑ablation procedures, the OneRF Brain Ablation System competes with Medtronic, Monteris Medical and Clearpoint’s LITT technology. In the trigeminal neuralgia market, the OneRF TN Ablation System is positioned against Boston Scientific and Avanos RF ablation systems as well as balloon‑compression approaches. For basal vertebral nerve ablation and spinal cord stimulation initiatives under development, the company expects competition from Boston Scientific, Stryker’s BVNA systems, and spinal cord stimulator leaders such as Medtronic, Boston Scientific, Abbott, Globus and Biotronik. In drug delivery, the principal rivals are Clearpoint and Sophysa’s (CED) platforms. NeuroOne differentiates itself through its thin‑film electrode technology that enables less‑invasive percutaneous placement, multi‑contact probes for greater precision, and integrated diagnostic‑therapeutic functionality that reduces the need for multiple devices. Additionally, its scalable automated manufacturing process supports cost‑competitive production and consistent product quality.

NeuroOne Medical Technologies Corporation serves hospitals, neurosurgeons, neurologists and pain management specialists that perform intracranial monitoring, ablation and stimulation procedures. Through its distribution arrangement with Zimmer Biomet, the company’s products reach approximately 188 Level 4 epilepsy centers across the United States. Specific collaborators and early adopters identified in the filing include the Mayo Clinic, the University of Wisconsin‑Madison, the Cleveland Clinic and Emory University, which have engaged in pre‑clinical or clinical testing of NeuroOne’s technology. The OneRF TN Ablation System, although in a limited release, is targeted at physicians treating trigeminal neuralgia and chronic facial pain.

Investment Thesis

▲ Bull case

NeuroOne is positioned to capitalize on significant international expansion opportunities following the imminent ISO 13485 certification of its Minnesota manufacturing facility, which is expected in the latter part of 2026. This certification is a prerequisite for selling medical devices in key regulated markets such as the European Union, Canada, and Japan. Management highlighted that the company is actively working with Zimmer Biomet to leverage their established international distribution network, particularly in geographies that recognize FDA clearance, thereby minimizing additional regulatory hurdles. The international opportunity is especially compelling given the global prevalence of drug-resistant epilepsy and trigeminal neuralgia, where NeuroOne’s minimally invasive, single-placement ablation technology offers distinct clinical advantages over legacy systems requiring multiple probe insertions. Unlike temporary setbacks, this represents a structural shift in market access, as the company transitions from a purely domestic player to one with a viable pathway for scalable international revenue. The fact that Zimmer Biomet has expressed willingness to support regulatory submissions further de-risks this initiative, suggesting that international sales could begin contributing meaningfully to top-line growth as early as Q1 FY27, well ahead of current investor expectations that remain fixated on near-term domestic performance.
The drug delivery program, though not included in current fiscal 2026 guidance, represents a high-potential hidden catalyst that could unlock substantial long-term value through strategic partnerships and expanded clinical applications. NeuroOne has already initiated a collaboration with the University of Minnesota’s Division of Epilepsy to evaluate next-generation epilepsy therapies using its drug delivery platform, signaling strong academic interest and validation of the technology’s versatility beyond ablation. The platform’s ability to deliver therapeutic agents directly to targeted neural sites—combined with the reusable OneRF generator—creates a differentiated value proposition in the growing field of targeted drug delivery for neurological disorders. Management explicitly stated they are evaluating distributors for commercialization, indicating a capital-efficient go-to-market strategy that avoids the need for a direct sales force. Given the rising prevalence of chronic neurological conditions and the limitations of systemic drug therapies, this program could address a significant unmet need. The collaboration with a major academic medical center suggests potential for investigational device exemption (IDE) studies that could generate clinical data to support broader regulatory clearances, transforming what is currently viewed as a speculative R&D effort into a near-term revenue driver with multiple indication possibilities.
NeuroOne’s trigeminal nerve ablation system is experiencing accelerating adoption due to favorable procedural economics and clinician workflow benefits that are underappreciated by the market, setting the stage for rapid organic growth within the existing installed base of OneRF generators. The company reported 16 successful procedures to date with all patients achieving pain-free outcomes, and neurosurgeons are increasingly stacking these cases in a single day due to the absence of lengthy waiting periods required for brain ablation procedures to identify epileptic foci. This operational efficiency—enabled by the device’s multi-contact electrode design allowing single-placement, multi-point testing—reduces procedure time, increases daily throughput, and enhances patient comfort, making it highly attractive to time-constrained neurosurgical practices. Unlike temporary adoption spikes, this reflects a structural advantage in neuromodulation workflows that encourages repeat utilization and word-of-mouth referrals among physician networks. The absence of a dedicated CPT code, while often viewed as a risk, actually facilitates faster adoption by allowing billing under existing neurosurgical codes, reducing administrative friction. As more physicians witness consistent outcomes and procedural ease, adoption is likely to accelerate organically within current centers, driving higher utilization rates per generator and expanding the addressable market beyond the initial $780 million trigeminal neuralgia estimate to include adjacent facial pain indications.

NeuroOne is positioned to capitalize on significant international expansion opportunities following the imminent ISO 13485 certification of its Minnesota manufacturing facility, which is expected in the latter part of 2026. This certification is a prerequisite for selling medical devices in key regulated markets such as the European Union, Canada, and Japan. Management highlighted that the company is actively working with Zimmer Biomet to leverage their established international distribution network, particularly in geographies that recognize FDA clearance, thereby minimizing additional regulatory hurdles. The international opportunity is especially compelling given the global prevalence of drug-resistant epilepsy and trigeminal neuralgia, where NeuroOne’s minimally invasive, single-placement ablation technology offers distinct clinical advantages over legacy systems requiring multiple probe insertions. Unlike temporary setbacks, this represents a structural shift in market access, as the company transitions from a purely domestic player to one with a viable pathway for scalable international revenue. The fact that Zimmer Biomet has expressed willingness to support regulatory submissions further de-risks this initiative, suggesting that international sales could begin contributing meaningfully to top-line growth as early as Q1 FY27, well ahead of current investor expectations that remain fixated on near-term domestic performance.
The drug delivery program, though not included in current fiscal 2026 guidance, represents a high-potential hidden catalyst that could unlock substantial long-term value through strategic partnerships and expanded clinical applications. NeuroOne has already initiated a collaboration with the University of Minnesota’s Division of Epilepsy to evaluate next-generation epilepsy therapies using its drug delivery platform, signaling strong academic interest and validation of the technology’s versatility beyond ablation. The platform’s ability to deliver therapeutic agents directly to targeted neural sites—combined with the reusable OneRF generator—creates a differentiated value proposition in the growing field of targeted drug delivery for neurological disorders. Management explicitly stated they are evaluating distributors for commercialization, indicating a capital-efficient go-to-market strategy that avoids the need for a direct sales force. Given the rising prevalence of chronic neurological conditions and the limitations of systemic drug therapies, this program could address a significant unmet need. The collaboration with a major academic medical center suggests potential for investigational device exemption (IDE) studies that could generate clinical data to support broader regulatory clearances, transforming what is currently viewed as a speculative R&D effort into a near-term revenue driver with multiple indication possibilities.
NeuroOne’s trigeminal nerve ablation system is experiencing accelerating adoption due to favorable procedural economics and clinician workflow benefits that are underappreciated by the market, setting the stage for rapid organic growth within the existing installed base of OneRF generators. The company reported 16 successful procedures to date with all patients achieving pain-free outcomes, and neurosurgeons are increasingly stacking these cases in a single day due to the absence of lengthy waiting periods required for brain ablation procedures to identify epileptic foci. This operational efficiency—enabled by the device’s multi-contact electrode design allowing single-placement, multi-point testing—reduces procedure time, increases daily throughput, and enhances patient comfort, making it highly attractive to time-constrained neurosurgical practices. Unlike temporary adoption spikes, this reflects a structural advantage in neuromodulation workflows that encourages repeat utilization and word-of-mouth referrals among physician networks. The absence of a dedicated CPT code, while often viewed as a risk, actually facilitates faster adoption by allowing billing under existing neurosurgical codes, reducing administrative friction. As more physicians witness consistent outcomes and procedural ease, adoption is likely to accelerate organically within current centers, driving higher utilization rates per generator and expanding the addressable market beyond the initial $780 million trigeminal neuralgia estimate to include adjacent facial pain indications.

▼ Bear case

NeuroOne’s path to profitability remains severely constrained by persistent operating losses and a deteriorating cash position, with management offering no credible timeline for achieving sustainable positive cash flow despite repeated assurances of imminent catalysts. The company reported a net loss of $3.5 million for the first six months of fiscal 2026, a stark contrast to the $0.5 million loss in the prior year period, primarily due to the absence of the $3 million in license revenue from Zimmer Biomet that previously flattered results. While product revenue grew 13% year-over-year to $5.3 million for the six-month period, this growth is insufficient to offset fixed operating expenses of $6.7 million, which remained flat year-over-year despite declining gross margins (from 57.9% to 54.0%). Crucially, cash and cash equivalents declined from $6.6 million at the end of fiscal Q2 2025 to just $2.8 million by March 31, 2026, implying a cash burn rate that could exhaust reserves within two to three quarters without additional financing. Management’s reliance on future international sales and drug delivery commercialization—both of which face significant regulatory and partnership execution risks—does not alter the near-term reality that the company is burning cash at an unsustainable pace while generating minimal gross profit to cover overhead. The CFO transition, while presented as seamless, removes a key financial steward with over five years of tenure just as the company faces its most critical liquidity test, introducing execution risk during a period requiring stringent capital discipline.
The company’s international expansion strategy is overly dependent on Zimmer Biomet’s willingness and capacity to prioritize NeuroOne’s products within its broader portfolio, creating a significant single-point-of-failure risk that management has not adequately addressed. Although NeuroOne hopes to launch internationally with Zimmer Biomet by leveraging their distribution rights in certain geographies, the transcript reveals uncertainty about coverage for additional regions, with David Rosa acknowledging they may need to partner with other distributors for territories Zimmer has not signed up for—yet provided no concrete plan, timeline, or progress on securing such alternatives. This vagueness suggests the company lacks a independent international commercialization capability and is effectively outsourcing a core growth lever to a partner whose incentives may not align with NeuroOne’s priorities. Zimmer Biomet, as a large diversified medical device company, may deprioritize NeuroOne’s niche ablation products in favor of higher-volume or more strategically aligned offerings, especially if regulatory processes in target markets prove lengthy or complex. The absence of any disclosed milestones, regulatory submission timelines, or committed investment from Zimmer for co-promotion indicates that international sales remain speculative and contingent on external factors beyond NeuroOne’s control, making this a fragile rather than structural catalyst for growth.
NeuroOne’s drug delivery program, while touted as a future opportunity, faces substantial scientific, regulatory, and commercialization hurdles that are being downplayed in favor of optimistic narratives, with no clear path to meaningful near-term revenue generation. Management stated the system will be available for investigational use or animal studies in the second half of fiscal 2026, but explicitly noted they do not expect major contributions from this area due to timing late in the fiscal year—effectively admitting it will not impact 2026 results. The collaboration with the University of Minnesota, while academically promising, remains at an early stage focused on therapy evaluation, not device commercialization or pivotal trials. Critical unanswered questions include the sterilization and packaging validation timeline (noted as taking ~3 months but with no start date provided), the lack of a defined regulatory pathway for human use (beyond IDE studies), and the absence of any identified pharmaceutical partners for co-development or formulation support. Without a clear IND or IDE submission plan, preclinical data package, or strategy to navigate the FDA’s stringent requirements for combination products, the program risks prolonged delays. Furthermore, targeting distributors for commercialization assumes market demand exists, yet there is no evidence of physician or institutional demand for a novel neural drug delivery platform outside of epilepsy research niches, making this more a speculative technology play than an imminent revenue driver.

NeuroOne’s path to profitability remains severely constrained by persistent operating losses and a deteriorating cash position, with management offering no credible timeline for achieving sustainable positive cash flow despite repeated assurances of imminent catalysts. The company reported a net loss of $3.5 million for the first six months of fiscal 2026, a stark contrast to the $0.5 million loss in the prior year period, primarily due to the absence of the $3 million in license revenue from Zimmer Biomet that previously flattered results. While product revenue grew 13% year-over-year to $5.3 million for the six-month period, this growth is insufficient to offset fixed operating expenses of $6.7 million, which remained flat year-over-year despite declining gross margins (from 57.9% to 54.0%). Crucially, cash and cash equivalents declined from $6.6 million at the end of fiscal Q2 2025 to just $2.8 million by March 31, 2026, implying a cash burn rate that could exhaust reserves within two to three quarters without additional financing. Management’s reliance on future international sales and drug delivery commercialization—both of which face significant regulatory and partnership execution risks—does not alter the near-term reality that the company is burning cash at an unsustainable pace while generating minimal gross profit to cover overhead. The CFO transition, while presented as seamless, removes a key financial steward with over five years of tenure just as the company faces its most critical liquidity test, introducing execution risk during a period requiring stringent capital discipline.
The company’s international expansion strategy is overly dependent on Zimmer Biomet’s willingness and capacity to prioritize NeuroOne’s products within its broader portfolio, creating a significant single-point-of-failure risk that management has not adequately addressed. Although NeuroOne hopes to launch internationally with Zimmer Biomet by leveraging their distribution rights in certain geographies, the transcript reveals uncertainty about coverage for additional regions, with David Rosa acknowledging they may need to partner with other distributors for territories Zimmer has not signed up for—yet provided no concrete plan, timeline, or progress on securing such alternatives. This vagueness suggests the company lacks a independent international commercialization capability and is effectively outsourcing a core growth lever to a partner whose incentives may not align with NeuroOne’s priorities. Zimmer Biomet, as a large diversified medical device company, may deprioritize NeuroOne’s niche ablation products in favor of higher-volume or more strategically aligned offerings, especially if regulatory processes in target markets prove lengthy or complex. The absence of any disclosed milestones, regulatory submission timelines, or committed investment from Zimmer for co-promotion indicates that international sales remain speculative and contingent on external factors beyond NeuroOne’s control, making this a fragile rather than structural catalyst for growth.
NeuroOne’s drug delivery program, while touted as a future opportunity, faces substantial scientific, regulatory, and commercialization hurdles that are being downplayed in favor of optimistic narratives, with no clear path to meaningful near-term revenue generation. Management stated the system will be available for investigational use or animal studies in the second half of fiscal 2026, but explicitly noted they do not expect major contributions from this area due to timing late in the fiscal year—effectively admitting it will not impact 2026 results. The collaboration with the University of Minnesota, while academically promising, remains at an early stage focused on therapy evaluation, not device commercialization or pivotal trials. Critical unanswered questions include the sterilization and packaging validation timeline (noted as taking ~3 months but with no start date provided), the lack of a defined regulatory pathway for human use (beyond IDE studies), and the absence of any identified pharmaceutical partners for co-development or formulation support. Without a clear IND or IDE submission plan, preclinical data package, or strategy to navigate the FDA’s stringent requirements for combination products, the program risks prolonged delays. Furthermore, targeting distributors for commercialization assumes market demand exists, yet there is no evidence of physician or institutional demand for a novel neural drug delivery platform outside of epilepsy research niches, making this more a speculative technology play than an imminent revenue driver.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password